Free shipping on all orders over $ 500
Cemiplimab (Libtayo) is a human monoclonal antibody injected intravenously that targets programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands PD-1 and PD-L2. Source: HEK293
In vivo: Cemiplimab (REGN2810) binds to the humanized PD-1 receptor and inhibits tumor growth in MC38 mice in human PD-1 knockout mice. REGN2810 has a high affinity for cynomolgus monkey PD-1, and its pharmacokinetics and toxicology were studied in cynomolgus monkey. High dose REGN2810 was well tolerated without adverse immune-related effects. In vitro: In cell-based assays, REGN2810 reversed PD-1-dependent attenuation of T-cell receptor signaling and enhanced human primary T-cell responses.
| CAS Number | 1801342-60-8 |
| Solubility (25°C) | N/A |
| Storage | 4°C , protect from light , dry , sealed |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Krishnansu S Tewari, et al. N Engl J Med. Survival with Cemiplimab in Recurrent Cervical Cancer
[4] Arnold Lee, et al. Drugs. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma
| Related PD-1/PD-L1 Products |
|---|
| Human PD-L1 inhibitor V
Human PD-L1 inhibitor V is a human PD-1 protein binding peptide with a Kd value of 3.32 μM that inhibits the binding of human PD-1/PD-L1.Sequence:Leu-Asp-Tyr-Val-Asn-Arg-Arg-Lys-Met-Tyr-Gln. |
| ARB-272572
ARB-272572 is a potent small molecule PD-L1 inhibitor with an IC50 value of 400 pM. |
| AUNP-12
AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway. |
| CA-170
CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. |
| Evixapodlin
Evixapodlin (PD-1/ PD-L1-in 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. Evixapodlin has anti-cancer and anti-virus properties. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
